NCT07377643 2026-02-25IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Phase 3 Recruiting540 enrolled
NCT04273555 2026-02-06Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR ImagingUniversity of Alabama at BirminghamPhase 1/2 Withdrawn
NCT06830889 2026-01-22A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant TherapySichuan Baili Pharmaceutical Co., Ltd.Phase 3 Recruiting1,450 enrolled